Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Polypharmacy in schizophrenia

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Benzodiazepines and antipsychotics in severe mental illness

    Publikation: Bog/antologi/afhandling/rapportDoktordisputatsForskning

  2. Association between global functioning at first schizophrenia diagnosis and treatment resistance

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Schizophrenia is a severe mental disorder characterized by a heterogeneous symptom profile which comprises a clinical platform for widespread use of polypharmacy even though antipsychotic monotherapy is the recommended treatment regimen. This narrative review provides a summary of the current gap between evidence and practice for use of antipsychotic combination therapy in patients with schizophrenia. Antipsychotic polypharmacy is frequently prescribed instead of following international consensus of clozapine monotherapy in treatment-resistant patients. Antipsychotic-benzodiazepine combination therapy clearly has a role in the treatment of acute agitation whereas there is no evidence to support an effect on core schizophrenia symptoms when chronically prescribed. Antidepressants are typically added to antipsychotic treatment in case of persistent negative symptoms. Available evidence suggests that antidepressants may improve negative symptom control in schizophrenia. Combining an antipsychotic with an antiepileptic is not supported by any firm evidence, but individual mood stabilizers have come out positively in single trials. Generally, the evidence base for polypharmacy in schizophrenia maintenance treatment is sparse but may be warranted in certain clinical situations. Therapeutic benefits and side effects should be carefully monitored and considered to ensure a beneficial risk-benefit ratio if prescribing polypharmacy for specific clinical indications.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
ISSN1742-7843
DOI
StatusE-pub ahead of print - 6 jan. 2020

Bibliografisk note

© 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.

ID: 59086833